Clinical characteristics, adherence to anticoagulation therapy and prognosis in patients with atrial fibrillation: a real-life study

Table 3 Independent Influences on Prescribing Inappropriate OAC Doses in NVAF Patients

Inappropriate dose	Impact factor	Number of events	OR(95%CI)	P-value
2018
Standard Dose	Renal insufficiency	10	0.334(0.128-0.872)	0.025
Underdosing	Renal insufficiency	9	0.334(0.128-0.872)	0.025
Standard Dose	Diabetes	26	7.080(1.007-49.761)	0.049
Overdosing	Diabetes	5	7.080(1.007-49.761)	0.049
2023
Standard Dose	Age	-	1.043(1.020-1.066)	0.000
Underdosing	Age	-	1.043(1.020-1.066)	0.000
Standard Dose	Renal insufficiency	128	0.381(0.253-0.573)	0.000
Underdosing	Renal insufficiency	87	0.381(0.253-0.573)	0.000
Standard Dose	Rivaroxaban	20	10.725(6.177-18.622)	0.000
Underdosing	Rivaroxaban	109	10.725(6.177-18.622)	0.000
Standard Dose	BMI	-	1.318(1.040-1.671)	0.022
Overdosing	BMI	-	1.318(1.040-1.671)	0.022
Standard Dose	Hypertension	185	0.323(0.125-0.833)	0.019
Overdosing	Hypertension	19	0.323(0.125-0.833)	0.019
Standard Dose	Renal insufficiency	128	2.791(1.189-6.551)	0.018
Overdosing	Renal insufficiency	25	2.791(1.189-6.551)	0.018
Standard Dose	HAS-BLED≥3	213	5.154(1.555-17.088)	0.007
Overdosing	HAS-BLED≥3	29	5.154(1.555-17.088)	0.007
Standard Dose	Dabigatran	9	7.274(1.584-33.391)	0.011
Overdosing	Dabigatran	3	7.274(1.584-33.391)	0.011
Standard Dose	Rivaroxaban	20	6.935(2.794-17.214)	0.000
Overdosing	Rivaroxaban	12	6.935(2.794-17.214)	0.000

OAC: Oral anticoagulant, NVAF: Non-valvular atrial fibrillation, OR: Odds ratio, CI: Confidence interval, BMI: Body mass index
-:Continuous variables; Statistically different at P < 0.05

ISSN: 1471-2261